Aims and Scope
International Journal of Multiple Sclerosis and Related Disorders (JSC) is a peer-reviewed, open-access journal dedicated to publishing the latest advancements in the diagnosis, treatment, and management of multiple sclerosis (MS) and related neurological conditions. JSC serves as a global platform for clinicians, researchers, and healthcare professionals to share cutting-edge research, clinical insights, and innovative approaches to understanding and treating MS and its associated disorders.
Scope and Focus:
JSC covers a broad spectrum of topics related to multiple sclerosis and its related neurological conditions, including but not limited to:
- Pathophysiology and Disease Mechanisms: Advances in understanding the underlying biology of MS and related disorders.
- Diagnosis and Biomarkers: Novel diagnostic techniques, imaging, and biomarker discovery.
- Therapeutic Approaches: Pharmacological treatments, immunotherapies, and emerging therapeutic strategies.
- Neuroimmunology and Inflammation: The immune system’s role in MS and autoimmune neurological diseases.
- Epidemiology and Risk Factors: Genetic, environmental, and lifestyle factors influencing MS progression.
- Disease Progression and Prognosis: Studies on relapse patterns, disability progression, and long-term outcomes.
- Rehabilitation and Symptom Management: Strategies to manage symptoms such as fatigue, pain, and cognitive impairment.
- Neuropsychology and Mental Health: Cognitive dysfunction, depression, and psychological impacts of MS.
- Pediatric and Atypical MS: Research on early-onset and uncommon forms of MS and related disorders.
- Emerging Technologies and Artificial Intelligence in MS Research: Innovations in neuroimaging, digital health, and artificial intelligence applications.
We have included a list of keywords to indicate the scope of the journal. If you have any questions, please do not hesitate to contact us at [email protected]
- Biochemistry
- Genetics
- Psychology
- Virology
- Autoimmune disease
- Atrophy
- Nootropics
- Diplopia
- Neuroplasticity
- Exacerbation
- Comorbidity
- Microbiome
- Accelerometer
- Neuromyelitis optica
- Neurology
- Immunology
- Lymphopenia
- Adrenoleukodystrophy
- Demyelination
- Dysesthesias
- Fingolimod
- Ozanimod
- Brain development
- Causes of multiple sclerosis
- Clinically isolated syndrome
- Neurological assessment
- Types of multiple sclerosis
- Epidemiology and genetics
- Neuroimmunological disorders
- Autoimmune diseases of the central nervous system
- Multiple sclerosis
- Neuroinflammation
- Central nervous system
- Myelin
- Immune system dysfunction
- Relapsing-remitting multiple sclerosis
- Primary progressive multiple sclerosis
- Secondary progressive multiple sclerosis
- Progressive-relapsing multiple sclerosis
- Multiple sclerosis diagnosis
- Magnetic resonance imaging
- Lumbar puncture
- Multiple sclerosis symptoms
- Multiple sclerosis relapses
- Multiple sclerosis treatment
- Disease-modifying therapies
- Interferon beta
- Glatiramer acetate
- Teriflunomide
- Dimethyl fumarate
- Natalizumab
- Alemtuzumab
- Ocrelizumab
- Rituximab
- Cladribine
- Siponimod
- B-cell therapies
- T-cell therapies
- Stem cell therapies
- Multiple sclerosis rehabilitation
- Physical therapy
- Occupational therapy
- Speech therapy
- Cognitive rehabilitation
